Tryp Therapeutics (CSE: TRYP) is a pharmaceutical company focused on identifying and developing clinical-stage compounds for
diseases with high unmet medical needs through accelerated regulatory pathways.
Download the company's investor presentation and receive corporate updates:
Innovative Drug Pipeline
Experienced Management Team
Chief Executive Officer
James Kuo, MD, MBA
President & Chief Scientific Officer
James Gilligan, PhD, MSIB
Chief Operating Officer
Tom D’Orazio, MBA
A global leader in life sciences, business development and corporate finance including past stints as CEO of BioMicro Systems and Discovery Laboratories (NASDAQ: DSCO) and head of business development at Myriad Genetics (NASDAQ: MYGN).
More than 35 years of experience in the life sciences industry, including R&D, clinical development, international regulatory affairs and manufacturing, including as Co-Founder and Managing Partner of The Bracken Group.
Extensive experience leading the development and commercialization of vaccines, drugs, radiopharmaceuticals, and biologics. Formerly the CEO of ImmunoPrecise Antibodies (TSXV: IPA) Successfully in-licensed two products and succeeded in getting Health Canada approval for both drugs in head & neck cancer and prostate cancer respectively.